

Table 1: PML risk estimates per 1,000 patients in anti-JC virus antibody positive patients*

Duration of Tysabri use	No prior use of immunosuppressants				Prior use of immunosuppressants
	No index value	Index 0.9 or less	Index 0.9 to 1.5	Index more than 1.5	
1-12 months	0.1	0.1	0.1	0.2	0.3
13-24 months	0.6	0.1	0.3	0.9	0.4
25-36 months	2	0.2	0.8	3	4
37-48 months	4	0.4	2	7	8
49-60 months	5	0.5	2	8	8
61-72 months	6	0.6	3	10	6

*from Tysabri Physician Information and Management Guidelines